Nutrition Business Journal

Ambiguity Creeps Into Report on GAIT Study of Arthritis Supplements

Negative and positive headlines generated; industry intrigued by mixed messages.

When NIH-funded researchers completed their rigorous Glucosamin/ chondroitin Arthritis Intervention Trial (GAIT) last year, there seemed to be nothing ambiguous about their primary conclusion: A combination of glucosamine and chondroitin was “effective in treating moderate to severe knee pain from osteoarthritis,” according to an abstract of the study results.

But when lead investigator Daniel O. Clegg, who is chief of rheumatology at the University of Utah, presented the research at

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.